Ikarian Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

Ikarian Capital’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.49M	Buy	1,053,797 +799,485	+314%	+$2.04M	0.2%	88
2025 Q4	$537K	Sell	254,312 -11,457	-4%	-$22.7K	0.04%	137
2025 Q3	$454K	Hold	265,769	–	–	0.05%	139
2025 Q2	$308K	Hold	265,769	–	–	0.06%	103
2025 Q1	$292K	Hold	265,769	–	–	0.04%	129
2024 Q4	$457K	Sell	265,769 -666	-0.2%	-$1.6K	0.06%	131
2024 Q3	$661K	Hold	266,435	–	–	0.09%	112
2024 Q2	$645K	Hold	266,435	–	–	0.11%	87
2024 Q1	$1.08M	Sell	266,435 -48,830	-15%	-$184K	0.12%	103
2023 Q4	$1.21M	Hold	315,265	–	–	0.11%	94
2023 Q3	$1.31M	Sell	315,265 -339,680	-52%	-$2.1M	0.16%	94
2023 Q2	$3.15M	Buy	654,945 +400,000	+157%	+$1.91M	0.5%	51
2023 Q1	$1.04M	Hold	254,945	–	–	0.23%	76
2022 Q4	$1.38M	Sell	254,945 -95,055	-27%	-$639K	0.33%	46
2022 Q3	$3.51M	Buy	+350,000	New	+$2.01M	0.7%	44

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Ikarian Capital's ABOS Position: Q1 2026 in Review

Ikarian Capital increased its Acumen Pharmaceuticals (ABOS) stake by 314% in Q1 2026, buying an estimated $2.04M and bringing the position to 1,053,797 shares worth $2.49M. The position accounts for 0.2% of the portfolio, ranked #88.

Ikarian Capital first reported a position in ABOS in Q3 2022 and has held it in 15 quarters since. The position peaked at $3.51M in Q3 2022. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

Ikarian Capital held 1,053,797 shares of Acumen Pharmaceuticals worth $2.49M as of Q1 2026.
Ikarian Capital bought 799,485 Acumen Pharmaceuticals shares in Q1 2026, an estimated $2.04M.
Acumen Pharmaceuticals made up 0.2% of Ikarian Capital's portfolio in Q1 2026, its #88 holding.
Ikarian Capital first reported a position in Acumen Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Ikarian Capital's Acumen Pharmaceuticals position peaked at $3.51M in Q3 2022.
84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.